Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $11.9 million.

  • Kiniksa Pharmaceuticals International's Cash from Financing Activities rose 7788.91% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.5 million, marking a year-over-year increase of 15424.72%. This contributed to the annual value of $12.3 million for FY2024, which is 72046.82% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Cash from Financing Activities is $11.9 million, which was up 7788.91% from $10.7 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Cash from Financing Activities' 5-year high stood at $11.9 million during Q3 2025, with a 5-year trough of -$178000.0 in Q2 2024.
  • Moreover, its 5-year median value for Cash from Financing Activities was $1.1 million (2021), whereas its average is $2.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 21265.82% in 2024, then soared by 611011.24% in 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Cash from Financing Activities (Quarter) stood at $1.2 million in 2021, then decreased by 1.82% to $1.2 million in 2022, then tumbled by 41.6% to $695000.0 in 2023, then skyrocketed by 208.2% to $2.1 million in 2024, then surged by 455.51% to $11.9 million in 2025.
  • Its last three reported values are $11.9 million in Q3 2025, $10.7 million for Q2 2025, and $2.8 million during Q1 2025.